Betagenon : its lead AMPK activator drug candidate BG8702 has started IMP enabling studies in the UK

Jan 29, 2009 - Betagenon announced that its lead AMPK activator drug candidate BG8702 aimed for the treatment of type2 diabetes has started Investigational Medicinal Product enabling studies in the UK. The selected compound is derived from the in-house drug discovery AMPK activator program. Treatment with BG8702 leads to significant improvement of insulin sensitivity, glucose and triglyceride lowering in diabetic mouse models... Betagenon's Press Releases -